Citations

Showing 10 of 108083 citations.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Chesney, Jason , Collichio, Frances A. , Milhem, Mohammed , Hamid, Omid , Ross, Merrick I. , Friedlander, Philip , Garbe, Claus , Logan, Theodore F. , Chen, Lisa , Gansert, Jennifer, Andtbacka, Robert H.I. , Singh, Parminder , Collichio, Frances, Milhem, Mohammed M, Glaspy, John, Ross, Merrick, Hauschild, Axel, Lebbe, Celeste, Kim, Jenny J, Kaufman, Howard L, Milhem, Mohammed M , Puzanov, Igor , Singh, Parminder Pal , Glaspy, John A. , Hauschild, Axel , Lebbé, Célèste , Kim, Jaeyeon , Kaufman, Howard L. , Singh, Parminder

Mayo Clinic

Journal of Clinical Oncology | October 5, 2017 | Volume: 36 | Issue: 17 | Pages: 1658-1667

10.1200/jco.2017.73.7379 | PMID 28981385 Get It

Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor. Methods Patients with unresectable stages IIIB to IV melanoma, with no more than one prior therapy if BRAF wild-type, no more than two prior therapies if BRAF mutant, measurable/injectable disease, and without symptomatic autoimmunity or clinically significant immunosuppression were randomly assigned 1:1 to receive talimogene laherparepvec plus ipilimumab or ipilimumab alone. Talimogene laherparepvec treatment began in week 1 (first dose, ≤ 4 mL × 10 6 plaque-forming units/mL; after 3 weeks, ≤ 4 mL × 10 8 plaque-forming units/mL every 2 weeks). Ipilimumab (3 mg/kg every 3 weeks; up to four doses) began week 1 in the ipilimumab alone arm and week 6 in the combination arm. The primary end point was objective response rate evaluated by investigators per immune-related response criteria. Results One hundred ninety-eight patients were randomly assigned to talimogene laherparepvec plus ipilimumab (n = 98), or ipilimumab alone (n = 100). Thirty-eight patients (39%) in the combination arm and 18 patients (18%) in the ipilimumab arm had an objective response (odds ratio, 2.9; 95% CI, 1.5 to 5.5; P = .002). Responses were not limited to injected lesions; visceral lesion decreases were observed in 52% of patients in the combination arm and 23% of patients in the ipilimumab arm. Frequently occurring adverse events (AEs) included fatigue (combination, 59%; ipilimumab alone, 42%), chills (combination, 53%; ipilimumab alone, 3%), and diarrhea (combination, 42%; ipilimumab alone, 35%). Incidence of grade ≥ 3 AEs was 45% and 35%, respectively. Three patients in the combination arm had fatal AEs; none were treatment related. Conclusion The study met its primary end point; the objective response rate was significantly higher with talimogene laherparepvec plus ipilimumab versus ipilimumab alone. These data indicate that the combination has greater antitumor activity without additional safety concerns versus ipilimumab.
Challenges in Patient Enrollment and Retention in Clinical Studies for Alcoholic Hepatitis: Experience of the TREAT Consortium
Lourens, Spencer, Liangpunsakul, Suthat , Chalasani, Naga , Shah, Vijay H. , Kamath, Patrick S. , Puri, Puneet, Katz, Barry P., Radaeva, Svetlana , Crabb, David W. , Liangpunsakul, Suthat , Crabb, David W , Comerford, Megan , Sanyal, Arun J. , Puri, Puneet

Mayo Clinic

Alcoholism: Clinical and Experimental Research | October 5, 2017 | Volume: 41 | Issue: 12 | Pages: 2000-2006

10.1111/acer.13515 | PMID 28981151 Get It

The TREAT Consortium has carried out clinical studies on alcoholic hepatitis (AH) for over 4 years. We encountered problems with participant recruitment, retention, and eligibility for specific protocols. To improve our ability to carry out such trials, we reviewed recruitment screening logs, end of study logs, and surveyed study coordinators to learn the reasons for missing patients, why patients declined enrollment, and the number of patients eligible for treatment trials. Associations of the recruited subjects’ demographics with their adherence to follow‐up appointments were examined. Three hundred eight‐seven patients (AH and heavy drinking controls) were enrolled in the observational study, and 55 AH patients were recruited into treatment trials. About half of patients identified with AH could not be recruited; no specific reason could be determined for about two‐thirds of these. Among the patients who gave a reason for not participating, the most common reasons were feeling too sick to participate, desire to concentrate on abstinence, and lack of interest in research. Approximately a quarter of the AH patients met eligibility criteria for treatment trials for moderate or severe AH and we were able to recruit half to two‐thirds of those eligible. Approximately 35% of participants in the observational study returned for both 6‐ and 12‐month follow‐up visits. We did not identify biopsychosocial or demographic correlates of retention in the study. This analysis revealed that attempts at recruitment into trials for AH miss some subjects because of structural issues surrounding their hospital admission, and encounter a high rate of patient refusal to participate. Nonetheless, more than half of the patients who met the eligibility criteria for moderate or severe AH were entered into clinical trials. Retention rates for the observational study are relatively low. These findings need to be accounted for in clinical trial design and power analysis.
Dendriform Pulmonary Ossification in the Absence of Usual Interstitial Pneumonia: CT Features and Possible Association With Recurrent Acid Aspiration
Gruden, James F. , Green, Daniel B. , Legasto, Alan C. , Jensen, Eric A., Panse, Prasad M.

Mayo Clinic

American Journal of Roentgenology | October 5, 2017 | Volume: 209 | Issue: 6 | Pages: 1209-1215

10.2214/ajr.17.18063 | PMID 28981359 Get It

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia diagnosed by tranbronchoscopic cryoprobe biopsy technique
Patel, Ravi , Collazo‐Gonzalez, Carolina, Andrews, Arthur, Johnson, Jean Guffey, Rumbak, Mark J., Patel, Ravi , Smith, Maxwell L.

Mayo Clinic

Respirology Case Reports | October 5, 2017 | Volume: 5 | Issue: 6 | Pages: No page available

10.1002/rcr2.275 | PMID 29026608 Get It

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) remains a poorly understood clinical entity. It is currently classified as a premalignant condition by the World Health Organization (WHO). Symptoms are similar to those associated with obstructive lung disease, including breathlessness and cough. The presentation is often initially ascribed to other diseases such as asthma or chronic obstructive pulmonary disease. Here, we present what we believe is the first described case of DIPNECH diagnosed by transbronchoscopic cryoprobe biopsy. The patient presented with chronic cough, dyspnoea, pulmonary function tests consistent with obstruction, and a computed tomography (CT) scan of chest with multiple nodules. The patient went on to have transbronchoscopic cryoprobe biopsies of the lung, which confirmed the diagnosis of DIPNECH.
Detection of generalized tonic–clonic seizures using surface electromyographic monitoring
Halford, Jonathan J. , Sperling, Michael R. , Nair, Dileep , Dlugos, Dennis , Tatum, William O. , Harvey, Jay , Pollard, John R. , Faught, Edward, Henry, Thomas R. , Jetter, Gina M., Lie, Octavian V., Morgan, Lola, Girouard, Michael, Cardenas, Damon , Whitmire, Luke , Cavazos, José E , Noe, Katherine H. , Sperling, Michael R , Halford, Jonathan J , French, Jacqueline A. , Nair, Dileep R

Mayo Clinic

Epilepsia | October 5, 2017 | Volume: 58 | Issue: 11 | Pages: 1861-1869

10.1111/epi.13897 | PMID 28980702 Get It

Summary Objective A prospective multicenter phase III trial was undertaken to evaluate the performance and tolerability in the epilepsy monitoring unit ( EMU ) of an investigational wearable surface electromyographic ( sEMG ) monitoring system for the detection of generalized tonic–clonic seizures ( GTCSs ). Methods One hundred ninety‐nine patients with a history of GTCSs who were admitted to the EMU in 11 level IV epilepsy centers for clinically indicated video‐electroencephalographic monitoring also received sEMG monitoring with a wearable device that was worn on the arm over the biceps muscle. All recorded sEMG data were processed at a central site using a previously developed detection algorithm. Detected GTCSs were compared to events verified by a majority of three expert reviewers. Results For all subjects, the detection algorithm detected 35 of 46 (76%, 95% confidence interval [CI] = 0.61–0.87) of the GTCSs, with a positive predictive value ( PPV ) of 0.03 and a mean false alarm rate ( FAR ) of 2.52 per 24 h. For data recorded while the device was placed over the midline of the biceps muscle, the system detected 29 of 29 GTCSs (100%, 95% CI = 0.88–1.00), with a detection delay averaging 7.70 s, a PPV of 6.2%, and a mean FAR of 1.44 per 24 h. Mild to moderate adverse events were reported in 28% (55 of 199) of subjects and led to study withdrawal in 9% (17 of 199). These adverse events consisted mostly of skin irritation caused by the electrode patch that resolved without treatment. No serious adverse events were reported. Significance Detection of GTCSs using an sEMG monitoring device on the biceps is feasible. Proper positioning of this device is important for accuracy, and for some patients, minimizing the number of false positives may be challenging.
Innovative care models after liver transplant
Taner, C. Burcin , Keaveny, Andrew P.

Mayo Clinic

Clinical Liver Disease | October 5, 2017 | Volume: 10 | Issue: 3 | Pages: 68-71

10.1002/cld.656 | PMID 30992763 Get It

The pathological differential diagnosis of portal hypertension
Nakhleh, Raouf E.

Mayo Clinic

Clinical Liver Disease | October 5, 2017 | Volume: 10 | Issue: 3 | Pages: 57-62

10.1002/cld.655 | PMID 30992761 Get It

Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population‐based nested case‐control study
Kumar, Swarup , Schleck, C. D., Johnson, Michele L., Alexander, J.A., Katzka, David A. , Iyer, Prasad G. , Kumar, S , Iyer, P G , Drake, Matthew T. , Alexander, J. A.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 5, 2017 | Volume: 46 | Issue: 11-12 | Pages: 1094-1102

10.1111/apt.14345 | PMID 28980336 Get It

SummaryBackgroundProton pump inhibitors (PPI) are inconsistently associated with osteoporotic fractures. Barrett's oesophagus (BO) patients are treated with high PPI doses for prolonged periods, but there are limited data on the incidence of osteoporosis and fractures in this group pf patients.AimTo estimate the incidence of (and risk factors for) low bone mass (osteoporosis and/or osteopenia) related fractures in a population‐based BO cohort.MethodsAll subjects with BO and a diagnosis of osteoporosis and fractures were identified using Rochester Epidemiology Project resources. The incidence rates of all and osteoporotic fractures in these subjects were compared to an age‐ and gender similar population in Olmsted County to determine standardised incidence ratios (SIR). Predictors were assessed using Cox proportional hazards models.ResultsFive hundred and twenty‐one patients were included (median [IQR] age 61 [52, 72] years; 398 [76%] men) of whom 113 (21.7%) had fractures, and 46 (8.8%) had osteoporotic fractures. The incidence of all fractures and osteoporotic fractures was comparable to that of an age‐ and gender‐matched population (SIR 1.09; 95% CI 0.92‐1.29: SIR 1.05; 95% CI 0.85‐1.29). PPI use, dose or duration of use was not associated with osteoporotic fracture risk (HR 0.87; 95% CI 0.12‐6.39). Independent risk factors for osteoporotic fractures included older age, female gender and higher co‐morbidity index.ConclusionsThe incidence of osteoporotic fractures was not increased in BO patients compared to the general population. In addition, PPI use was not associated with increased fracture risk regardless of the duration of therapy or dose.
A population-based prospective study of optic neuritis
Soelberg, Kerstin , Jarius, Sven , Skejoe, HPB, Engberg, Henriette , Mehlsen, JJ, Nilsson, Anna Christine , Madsen, Jonna Skov , Reindl, Markus , Wildemann, Brigitte , Grauslund, Jakob , Kyvik, Kirsten Ohm , Smith, Terry J. , Lillevang, Søren Thue , Paul, Friedemann , Weinshenker, BG, Asgari, Nasrin , Weinshenker, Brian G. , Weinshenker, Brian G , Paul, Friedemann

Mayo Clinic

Multiple Sclerosis Journal | October 5, 2017 | Volume: 23 | Issue: 14 | Pages: 1893-1901

10.1177/1352458517734070 | PMID 28980518 Get It

Background: Optic neuritis (ON) is often associated with multiple sclerosis (MS). Early diagnosis is critical to optimal patient management. Objective: To estimate the incidence of acute ON and the rates of conversion to MS and antibody-mediated ON. Method: Population-based prospective study was performed in patients with ON from three ophthalmological departments and 44 practicing ophthalmologists from 2014 to 2016. Ophthalmological and neurological examination, magnetic resonance imaging (MRI), determination of aquaporin-4(AQP4)-IgG and myelin-oligodendrocyte glycoprotein (MOG)-IgG were investigated blindly. Results: In all, 63 patients were evaluated and 51 fulfilled the criteria for ON. All were Caucasian, with female:male ratio of 2.2:1 and a median age of 38 years (16–66); 44 (86%) had a single episode of ON (four bilateral), while 7/51 (14%) had recurrent ON. The overall age-specific incidence was 3.28 (2.44–4.31) per 100,000 person years, 2.02 for men and 4.57 for women. At follow-up, 20 patients met the diagnostic criteria for MS, MRI lesions disseminated in space and time in 17/20 patients. AQP4-IgG was detected in none, MOG-IgG was detected in two patients. Conclusion: The prospective incidence of ON was estimated. MRI enabled a diagnosis of MS in a subgroup of patients. Antibody-mediated ON with specificity for MOG was detected in 4% of cases.